<DOC>
	<DOCNO>NCT01092559</DOCNO>
	<brief_summary>This open label phase 2 pilot study design evaluate safety , tolerability device performance GeNO nitrosyl delivery system right heart catheterization ( RHC ) participant pulmonary arterial hypertension ( PAH ) . All participant receive inhale nitric oxide oxygen nitric oxide air deliver nasal cannula . Hemodynamics , clinical laboratory clinical assessment data collect participant evaluate safety .</brief_summary>
	<brief_title>Pilot Study Evaluating Safety Performance GeNO NITROsyl Delivery System Inhaled Nitric Oxide</brief_title>
	<detailed_description>TREATMENT/FOLLOW-UP : Participants meet eligibility criterion receive open label nitric oxide 80 ppm via nasal cannula . Hemodynamic clinical laboratory clinical assessment data collect baseline , 15 minute inhale nitric oxide administration , post RHC procedure hospital discharge . Day 5 +/- 3 post RHC , telephone contact ass general health status .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>Have confirm diagnosis PAH , WHO Group 1. WHO Functional Class II III equivalent , PAH . Have clinically stable regard sign symptom PAH least 30 day prior RHC . May receive approve mono therapy combination PAH therapy . Females surgically sterile postmenopausal . Females chilbearing potential must negative pregnancy test must practice adequate birth control . Have new type chronic therapy ( include limit oxygen , different category vasodilator , diuretic , digoxin ) PAH add within ( 1 ) month RHC . Have PAH medication except anticoagulant discontinue within week prior RHC . Have evidence significant parenchymal lung disease evidence pulmonary function test within last six month CREST ( calcinosis , Raynaud phenomenon , esophageal dysmotility , sclerodactyly , telangiectasia ) syndrome Have history uncontrolled sleep apnea within three month RHC . Have history hemodynamically significant leftsided heart disease Have evidence leftsided heart disease Have disease associate pulmonary hypertension ( e.g . congenital systemictopulmonary shunt , sickle cell anemia , schistosomiasis ) . Documented uncontrolled systemic hypertension evidence systolic blood pressure great 160 mmHg diastolic blood pressure great 100 mmHg . Have use prescription appetite suppressant within 3 month prior wean/transition . Have chronic kidney disease stage IV bad requirement dialysis . Be receive investigational drug , place investigational device , participate investigational drug study within past 30 day . Have atrial septostomy . Have anemia ( hemoglobin &lt; 10 g/dL ) , active infection ongoing condition would interfere interpretation study assessment . Have serious lifethreatening disease condition associate PAH ( e.g . malignancy require aggressive chemotherapy , renal dialysis , etc. ) . Have unstable psychiatric status mentally incapable understand objective , nature consequence trial Participant pregnant lactating Significant , ongoing alcohol drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Diagnostic Techniques Procedures</keyword>
</DOC>